[Heart failure protection by SGLT2 inhibitors in patients with type 2 diabetes mellitus: evidence and possible mechanisms : A systematic review]
Related Experiment Video
Updated: Dec 6, 2025

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
Published on: November 29, 2024
Andreas J Rieth1,2, Christian W Hamm3,4,5, Christoph Wanner6
1Kerckhoff-Klinik, Abteilung für Kardiologie, Campus Kerckhoff der Justus-Liebig-Universität Gießen, Benekestr. 2-8, 61231, Bad Nauheim, Deutschland. a.rieth@kerckhoff-klinik.de.
Background:
Renal sodium-glucose cotransporter‑2 (SGLT2) inhibitors seem to have a cardioprotective effect beyond the antidiabetic effect. The underlying mechanisms are unclear.
Methods:
Selective search in PubMed with a focus on heart failure endpoints and possible mechanisms of action.
Results:
During treatment with three of the substances analyzed, there were fewer hospitalizations for heart failure compared with placebo; however, the numbers needed to treat within the primary analyses were relatively high (72-117). We found that loss of weight and lowering of blood pressure were more pronounced during treatment with verum than with placebo and an association of the preventive effect with more severely impaired renal function.
Conclusion:
The SGLT2 inhibitors show a moderate heart failure protective effect in diabetic patients. It is likely that a nephroprotective effect with modulation of the cardiorenal interaction is an important part of the mechanism of action but this must be substantiated in further investigations.
Insights
Sodium-glucose cotransporter-2 (SGLT2) inhibitors offer moderate heart failure protection in diabetic patients. Mechanisms may involve kidney protection and cardiorenal interaction, requiring further study.
Area of Science:
- Cardiology
- Nephrology
- Pharmacology
Background:
- Sodium-glucose cotransporter-2 (SGLT2) inhibitors demonstrate cardioprotective effects beyond their antidiabetic properties.
- The precise mechanisms underlying these cardiovascular benefits remain largely undetermined.
Purpose of the Study:
- To investigate the cardioprotective effects of SGLT2 inhibitors, focusing on heart failure endpoints.
- To explore potential mechanisms of action for the observed cardioprotective effects.
Main Methods:
- A targeted literature search was conducted in PubMed.
- The search focused on studies reporting heart failure outcomes and potential SGLT2 inhibitor mechanisms.
Main Results:
- Treatment with certain SGLT2 inhibitors reduced heart failure hospitalizations compared to placebo, though numbers needed to treat were substantial (72-117).
- More pronounced weight loss and blood pressure reduction were observed with SGLT2 inhibitors.
- A correlation was found between the preventive effect and more severe renal impairment.
Conclusions:
- SGLT2 inhibitors provide a moderate protective effect against heart failure in diabetic individuals.
- Nephroprotective actions and modulation of cardiorenal interactions are likely key mechanisms.
- Further research is necessary to confirm these findings and elucidate the underlying pathways.
Related Concept Videos
Heart Failure V: Medical Management
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Oral Hypoglycemic Agents: Biguanides and Glitazones
Diabetes Mellitus: Type 2 and Gestational
Heart Failure II: Pathophysiology
Heart Failure Drugs: Diuretics

